Insulin Glargine Safety in Pregnancy
Open Access
- 6 October 2009
- journal article
- Published by American Diabetes Association in Diabetes Care
- Vol. 33 (1), 29-33
- https://doi.org/10.2337/dc09-1045
Abstract
OBJECTIVE Insulin glargine (Lantus) is an extended-action insulin analog with greater stability and duration of action than regular human insulin. The long duration of action and decreased incidence of hypoglycemia provide potential advantages for its use in pregnancy. However, the placental pharmacokinetics of insulin glargine have not been studied. Therefore, the objective of this study was to determine whether insulin glargine crosses the human placenta using the human perfused placental lobule technique. RESEARCH DESIGN AND METHODS Placentae were obtained with informed consent after elective cesarean section delivery of noncomplicated term pregnancies. Insulin glargine, at a therapeutic concentration of 150 pmol/l (20 μU/ml) was added to the maternal circulation. Additional experiments were carried out at insulin glargine concentrations 1,000-fold higher than therapeutic levels (150, 225, and 300 nmol/l). A subsequent perfusion for which the maternal circuit remained open and insulin glargine was continuously infused at 150 pmol/l was completed for further confirmation of findings. The appearance of insulin glargine in the fetal circulation was analyzed by a chemiluminescence immunoassay. RESULTS Results from perfusions carried out at therapeutic concentrations (150 pmol/l) of insulin glargine showed no detectable insulin glargine in the fetal circuit. After perfusion with very high insulin glargine concentrations of 150, 225, and 300 nmol/l, the rate of transfer remained low at 0.079 ± 0.01, 0.14, and 0.064 pmol · min−1 · g tissue−1, respectively. CONCLUSIONS Insulin glargine, when used at therapeutic concentrations, is not likely to cross the placenta.Keywords
This publication has 29 references indexed in Scilit:
- Use of glargine in pregnant women with Type 1 diabetes mellitus: A case-control studyClinical Therapeutics, 2008
- Managing Preexisting Diabetes for PregnancyDiabetes Care, 2008
- Survey of glargine use in 115 pregnant women with Type 1 diabetesDiabetic Medicine, 2008
- Use of insulin glargine during pregnancy: a case-control pilot studyBJOG: An International Journal of Obstetrics and Gynaecology, 2007
- Performance Evaluation and Cross-Reactivity from Insulin Analogs with the ARCHITECT Insulin Assay,Clinical Chemistry, 2006
- Effects of the Long-Acting Insulin Analog Insulin Glargine on Cultured Human Skeletal Muscle Cells: Comparisons to Insulin and IGF-IJournal of Clinical Endocrinology & Metabolism, 2001
- What degree of maternal metabolic control in women with type 1 diabetes is associated with normal body size and proportions in full-term infants?Diabetes Care, 2000
- Insulin Degradation: Progress and PotentialEndocrine Reviews, 1998
- Excursion of daily glucose profiles in pregnant women with IDDM: relationship with perinatal outcomejpme, 1997
- Transplacental passage of insulin in pregnant women with insulin-dependent diabetes mellitus. Its role in fetal macrosomiaInternational Journal of Gynecology & Obstetrics, 1991